# Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer

> **NCT01749397** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 29 (actual)

## Conditions studied

- Stage IV Fallopian Tube Cancer AJCC v6 and v7
- Stage IV Ovarian Cancer AJCC v6 and v7
- Stage IV Primary Peritoneal Cancer AJCC v7

## Interventions

- **DRUG:** Floxuridine
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study
- **DRUG:** Veliparib

## Key facts

- **NCT ID:** NCT01749397
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-07
- **Primary completion:** 2017-10-20
- **Final completion:** 2019-11-21
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2020-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01749397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01749397, "Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01749397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*